Skip to main content
. 2019 Dec 2;25:9179–9191. doi: 10.12659/MSM.918411

Figure 6.

Figure 6

Ranking of the direct and indirect comparisons for progression-free survival (PFS) for Fruq (fruquintinib), Reg (regorafenib), TAS (TAS-102), and PLA (placebo).